The shortage of drugs like Novo Nordisk A/S’ (NYSE:NVO) Ozempic, Wegovy, and Eli Lilly And Co’s (NYSE:LLY) Mounjaro and Zepbound have fueled an illicit market of counterfeit and diverted weight loss drugs, revealing an international issue that poses significant health risks. Last week, the FDA determined the shortage of Eli Lilly tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Also Read: Eli Lilly Issues Cease-And-Desist Letters to Compounders Over Weight-Loss Drug Copies As Shortage Resolves. A recent investigation by CNBC unveiled illegal sales and dru…